Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Person › Details

Helene Peyro-Saint-Paul (PathoQuest S.A.S.)

Peyro-Saint-Paul, Helene (PathoQuest 201610 CMO)

 

Organisation Organisation PathoQuest S.A.S.
Products Product iDTECT™ Blood test
  Product 2 Next Generation Sequencing (NGS) technology [about 2007/8]
     

PathoQuest S.A.S.. (10/27/16). "Press Release: PathoQuest Achieves CE Mark for the iDTECT Blood Test".

iDTECT™ Blood is the first NGS-based metagenomics test to be CE-IVD marked for the clinical identification of pathogens from blood samples


PathoQuest, a biotechnology company spun out from Institut Pasteur, today announced CE marking for iDTECT™ Blood, the company’s new clinical test offering a game-changing NGS-based metagenomics approach that improves the breadth of pathogen detection. Compared to the currently available solutions, iDTECT Blood, a proprietary sample-to-report test, provides clinicians a significantly improved method for detecting bacteria and viruses in blood samples from patients with suspected infections, especially immunocompromised patients.

“With this CE marking, PathoQuest will execute its global strategy and enter in early access programmes in selected countries.” stated Helene Peyro-Saint-Paul, M.D., PathoQuest’s Chief Medical Officer. “We believe iDTECT Blood will contribute to improved antibiotic stewardship and precision medicine strategies in infectious diseases, ultimately leading to better patient care.”

Professor Olivier Lortholary, Professor and Chair of the Department of Infectious and Tropical Diseases at Hôpital Necker-Enfants Malades, Paris, indicated that “In some clinical situations, especially when a patient is immunocompromised, culture and PCR tests are often unable to provide sufficient information to select the most appropriate targeted anti-infective therapy. With the availability of iDTECT Blood, clinicians will be able to expand their experience on the basis of the results already obtained in a proof-of-concept study completed at Necker-Enfants Malades and Européen Georges Pompidou hospitals (Paris, France) on a cohort of over 100 immuno-compromised patients.”

“CE marking of the iDTECT Blood test is a major milestone for PathoQuest. It validates the robustness of our sample-to-BioIT analysis solution, driven by PathoQuest’s proprietary iDTECT database and software” stated Jean-Francois Brepson, PathoQuest’s CEO.“This achievement materializes the leading position of PathoQuest in clinical metagenomics applied to infectiology. We are currently implementing the initial steps of our launch plan to make the test available to selected hospitals in Europe and in the US. We are also progressing towards our goal of establishing key strategic partnerships with companies and institutions which recognize the value of our NGS-based pathogen identification solution.”


About PathoQuest

Greater Pathogen Detection for Better Decisions

PathoQuest, a spin out of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improve pathogen detection in biological samples. PathoQuest’s technology, which combines NGS, a proprietary sample preparation process, applicable to several types of samples, a comprehensive and curated database of pathogens genomic sequence information and an automated analysis pipeline, provides clinicians and biopharma companies with a comprehensive analysis covering all known relevant human pathogens and bioproduction viral contaminants. This method overcomes the current limitation of pathogens detection, i.e. the need to specify the pathogens to be analyzed. PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first revenue-generating commercial application of its NGS testing approach, and is used by several major biopharma companies.

PathoQuest has also developed the iDTECT Blood Test, the first and only clinical CE Marked metagenomic test. This test provides clinicians with an improved method for detecting infectious organisms in blood samples from patients with suspected infections, in particular in immunocompromised groups. This new molecular diagnostic test is anticipated to contribute to better targeting of anti-microbial therapy, improved antibiotic stewardship and ultimately precision medicine in infectious diseases and better patient care.

   
Record changed: 2019-01-14

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px


More documents for Helene Peyro-Saint-Paul


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top